We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combined Behavioral and Pharmacologic Treatment of Polydrug Abuse

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00292123
First Posted: February 15, 2006
Last Update Posted: January 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Institute on Drug Abuse (NIDA)
February 14, 2006
February 15, 2006
January 12, 2017
June 1999
June 2006   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00292123 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Combined Behavioral and Pharmacologic Treatment of Polydrug Abuse
Not Provided
The primary goal of this study is to determine how contingency management can best be combined with standard or high doses of methadone to increase simultaneous abstinence from heroin and cocaine.
A study of people pmaintained on Methadone using contingency management
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
  • Opioid Dependence
  • Cocaine Abuse
  • Drug: Methadone
  • Behavioral: Contingency Management
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
August 2006
June 2006   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Opioid dependence; cocaine use

Exclusion Criteria:

  • Medical or psychiatric conditions that would contraindicate participation in a methadone maintenance study; inability to give informed consent; inability to attend clinic seven days a week
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00292123
NIDAIRP 326
No
Not Provided
Not Provided
Kenzie L. Preston, Ph.D., Principal Investigator, National Institute on Drug Abuse
National Institute on Drug Abuse (NIDA)
Not Provided
Principal Investigator: Kenzie Preston, PhD NIFA Intramural Research Program
National Institute on Drug Abuse (NIDA)
December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP
To Top